BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

175 related articles for article (PubMed ID: 16171822)

  • 1. Lysophosphatidic acid (LPA)-induced vascular endothelial growth factor (VEGF) by mesothelial cells and quantification of host-derived VEGF in malignant ascites.
    Sako A; Kitayama J; Shida D; Suzuki R; Sakai T; Ohta H; Nagawa H
    J Surg Res; 2006 Jan; 130(1):94-101. PubMed ID: 16171822
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lysophosphatidic acid (LPA) in malignant ascites stimulates motility of human pancreatic cancer cells through LPA1.
    Yamada T; Sato K; Komachi M; Malchinkhuu E; Tobo M; Kimura T; Kuwabara A; Yanagita Y; Ikeya T; Tanahashi Y; Ogawa T; Ohwada S; Morishita Y; Ohta H; Im DS; Tamoto K; Tomura H; Okajima F
    J Biol Chem; 2004 Feb; 279(8):6595-605. PubMed ID: 14660630
    [TBL] [Abstract][Full Text] [Related]  

  • 3. LPA1 receptors mediate stimulation, whereas LPA2 receptors mediate inhibition, of migration of pancreatic cancer cells in response to lysophosphatidic acid and malignant ascites.
    Komachi M; Tomura H; Malchinkhuu E; Tobo M; Mogi C; Yamada T; Kimura T; Kuwabara A; Ohta H; Im DS; Kurose H; Takeyoshi I; Sato K; Okajima F
    Carcinogenesis; 2009 Mar; 30(3):457-65. PubMed ID: 19129242
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysophosphatidic acid induction of vascular endothelial growth factor expression in human ovarian cancer cells.
    Hu YL; Tee MK; Goetzl EJ; Auersperg N; Mills GB; Ferrara N; Jaffe RB
    J Natl Cancer Inst; 2001 May; 93(10):762-8. PubMed ID: 11353786
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Lysophosphatidic acid is a major regulator of growth-regulated oncogene alpha in ovarian cancer.
    Lee Z; Swaby RF; Liang Y; Yu S; Liu S; Lu KH; Bast RC; Mills GB; Fang X
    Cancer Res; 2006 Mar; 66(5):2740-8. PubMed ID: 16510595
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Lysophosphatidic acid promotes secretion of VEGF by increasing expression of 150-kD Oxygen-regulated protein (ORP150) in mesenchymal stem cells.
    Wei H; Wang F; Wang X; Yang J; Li Z; Cong X; Chen X
    Biochim Biophys Acta; 2013 Aug; 1831(8):1426-34. PubMed ID: 23707263
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Lysophosphatidylethanolamine utilizes LPA(1) and CD97 in MDA-MB-231 breast cancer cells.
    Park SJ; Lee KP; Kang S; Chung HY; Bae YS; Okajima F; Im DS
    Cell Signal; 2013 Nov; 25(11):2147-54. PubMed ID: 23838008
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Dioleoyl phosphatidic acid increases intracellular Ca2+ through endogenous LPA receptors in C6 glioma and L2071 fibroblasts.
    Chang YJ; Kim YL; Lee YK; Sacket SJ; Kim K; Kim HL; Han M; Bae YS; Okajima F; Im DS
    Prostaglandins Other Lipid Mediat; 2007 Jun; 83(4):268-76. PubMed ID: 17499746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identification of heparin-binding EGF-like growth factor (HB-EGF) as a biomarker for lysophosphatidic acid receptor type 1 (LPA1) activation in human breast and prostate cancers.
    David M; Sahay D; Mege F; Descotes F; Leblanc R; Ribeiro J; Clézardin P; Peyruchaud O
    PLoS One; 2014; 9(5):e97771. PubMed ID: 24828490
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Lysophosphatidic acid as a mediator for proinflammatory agonists in a human corneal epithelial cell line.
    Zhang Z; Liu Z; Meier KE
    Am J Physiol Cell Physiol; 2006 Nov; 291(5):C1089-98. PubMed ID: 16760261
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Blocking lysophosphatidic acid receptor 1 signaling inhibits diabetic nephropathy in db/db mice.
    Li HY; Oh YS; Choi JW; Jung JY; Jun HS
    Kidney Int; 2017 Jun; 91(6):1362-1373. PubMed ID: 28111010
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Activation of hypoxia-inducible factor-1alpha is necessary for lysophosphatidic acid-induced vascular endothelial growth factor expression.
    Lee J; Park SY; Lee EK; Park CG; Chung HC; Rha SY; Kim YK; Bae GU; Kim BK; Han JW; Lee HY
    Clin Cancer Res; 2006 Nov; 12(21):6351-8. PubMed ID: 17085645
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lysophosphatidylserine induces calcium signaling through Ki16425/VPC32183-sensitive GPCR in bone marrow-derived mast cells and in C6 glioma and colon cancer cells.
    Kim K; Kim HL; Lee YK; Han M; Sacket SJ; Jo JY; Kim YL; Im DS
    Arch Pharm Res; 2008 Mar; 31(3):310-7. PubMed ID: 18409043
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lysophosphatidic acid-stimulated interleukin-6 and -8 synthesis through LPA1 receptors on human osteoblasts.
    Aki Y; Kondo A; Nakamura H; Togari A
    Arch Oral Biol; 2008 Mar; 53(3):207-13. PubMed ID: 17915188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Albendazole: a potent inhibitor of vascular endothelial growth factor and malignant ascites formation in OVCAR-3 tumor-bearing nude mice.
    Pourgholami MH; Yan Cai Z; Lu Y; Wang L; Morris DL
    Clin Cancer Res; 2006 Mar; 12(6):1928-35. PubMed ID: 16551879
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Orally active lysophosphatidic acid receptor antagonist attenuates pancreatic cancer invasion and metastasis in vivo.
    Komachi M; Sato K; Tobo M; Mogi C; Yamada T; Ohta H; Tomura H; Kimura T; Im DS; Yanagida K; Ishii S; Takeyoshi I; Okajima F
    Cancer Sci; 2012 Jun; 103(6):1099-104. PubMed ID: 22348348
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Lysophosphatidic acid receptor 1 antagonist ki16425 blunts abdominal and systemic inflammation in a mouse model of peritoneal sepsis.
    Zhao J; Wei J; Weathington N; Jacko AM; Huang H; Tsung A; Zhao Y
    Transl Res; 2015 Jul; 166(1):80-8. PubMed ID: 25701366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. LPA1 receptor activation promotes renal interstitial fibrosis.
    Pradère JP; Klein J; Grès S; Guigné C; Neau E; Valet P; Calise D; Chun J; Bascands JL; Saulnier-Blache JS; Schanstra JP
    J Am Soc Nephrol; 2007 Dec; 18(12):3110-8. PubMed ID: 18003779
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dual mode regulation of migration by lysophosphatidic acid in human gastric cancer cells.
    Shida D; Kitayama J; Yamaguchi H; Hama K; Aoki J; Arai H; Yamashita H; Mori K; Sako A; Konishi T; Watanabe T; Sakai T; Suzuki R; Ohta H; Takuwa Y; Nagawa H
    Exp Cell Res; 2004 Dec; 301(2):168-78. PubMed ID: 15530853
    [TBL] [Abstract][Full Text] [Related]  

  • 20. LPA
    Lin YC; Chen CC; Chen WM; Lu KY; Shen TL; Jou YC; Shen CH; Ohbayashi N; Kanaho Y; Huang YL; Lee H
    Biochim Biophys Acta Mol Cell Biol Lipids; 2018 Oct; 1863(10):1305-1315. PubMed ID: 30053596
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.